Skip to content


Yonsa, Zytiga (abiraterone) is a small molecule pharmaceutical. Abiraterone was first approved as Yonsa on 2011-04-28. It is used to treat castration-resistant prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against steroid 17-alpha-hydroxylase/17,20 lyase. Zytiga's patents are valid until 2034-05-20 (FDA).
Trade Name Zytiga
Common Name Abiraterone
Indication castration-resistant prostatic neoplasms, prostatic neoplasms
Drug Class Antiandrogens
Get full access now